Wearable sleep technology has merits—but a lack of evidence hinders clinical growth

Consumer sleep technologies like wearables and mobile apps are adept at collecting patient-generated health data, but lacking validation data and FDA clearance are hindering utilization, according to a position statement published in the May 15 issue of the Journal of Clinical Sleep Medicine.

In the current digital market, wearable and mobile health-related apps have become an easy-to-use method to collect patient data. But the technology has yet to be thoroughly tested in its accuracy in improving consumer sleep habits.

"Given the heightened public awareness of the importance of sleep, and of diagnosing and treating sleep disorders, I believe we will continue to see more patient-generated health data," said lead author Seema Khosla, MD, the medical director of the North Dakota Center for Sleep in Fargo, North Dakota. "We need some guidance both for how to utilize consumer sleep technology in our practice and also how to communicate with our patients about the specific metrics their devices are measuring."

Without validation data and FDA clearance, doubt in clinicians' minds about the capability of these technologies. Until barriers are addressed, the authors suggest patients should not replace validated diagnosis testing with information from digital sleep technology.

"While technology is advancing rapidly, and we are following the trends closely, consumer sleep devices currently are unable to diagnose sleep disorders," said Ilene Rosen, MD, MS, president of the American Academy of Sleep Medicine. "Individuals who are dissatisfied with their sleep, experiencing an ongoing sleep problem, or struggling with excessive daytime sleepiness or fatigue should discuss this important issue with a licensed medical provider, regardless of what their wearable or other consumer sleep technology device tells them."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup